Mirum Pharmaceuticals (MIRM) Stock Forecast, Price Target & Predictions
MIRM Stock Forecast
Mirum Pharmaceuticals stock forecast is as follows: an average price target of $54.50 (represents a 34.73% upside from MIRM’s last price of $40.45) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
MIRM Price Target
The average price target for Mirum Pharmaceuticals (MIRM) is $54.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $75.00 to $39.00. This represents a potential 34.73% upside from MIRM's last price of $40.45.
MIRM Analyst Ratings
According to 8 Wall Street analysts, Mirum Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MIRM stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Mirum Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Brian Skorney | Robert W. Baird | $44.00 | $38.96 | 12.94% | 8.78% |
| Jun 17, 2024 | Gavin Clark-Gartner | Evercore ISI | $62.00 | $33.00 | 87.88% | 53.28% |
| Jun 17, 2024 | Michael E Ulz | Morgan Stanley | $57.00 | $33.00 | 72.73% | 40.91% |
| Jun 17, 2024 | Ed Arce | H.C. Wainwright | $66.00 | $30.99 | 112.97% | 63.16% |
| Jun 17, 2024 | Brian Skorney | Robert W. Baird | $39.00 | $29.71 | 31.27% | -3.58% |
| May 23, 2024 | Joshua Schimmer | Cantor Fitzgerald | $45.00 | $25.75 | 74.79% | 11.25% |
| Apr 16, 2024 | Dae Gon Ha | Stifel Nicolaus | $48.00 | $24.01 | 99.92% | 18.67% |
| Mar 14, 2024 | Ed Arce | H.C. Wainwright | $58.00 | $28.17 | 105.89% | 43.39% |
| Jan 10, 2023 | - | Leerink Partners | $39.00 | $20.02 | 94.81% | -3.58% |
| Dec 14, 2022 | - | Leerink Partners | $50.00 | $18.01 | 177.62% | 23.61% |
The latest Mirum Pharmaceuticals stock forecast, released on Aug 08, 2024 by Brian Skorney from Robert W. Baird, set a price target of $44.00, which represents a 12.94% increase from the stock price at the time of the forecast ($38.96), and a 8.78% increase from MIRM last price ($40.45).
Mirum Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 8 |
| Avg Price Target | - | $44.00 | $52.38 |
| Last Closing Price | $40.45 | $40.45 | $40.45 |
| Upside/Downside | -100.00% | 8.78% | 29.49% |
In the current month, the average price target of Mirum Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mirum Pharmaceuticals's last price of $40.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 11, 2024 | Evercore ISI | Underperform | Underperform | Hold |
| Aug 08, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jun 18, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 17, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Jun 17, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 03, 2024 | Citigroup | Buy | Buy | Hold |
| May 23, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 09, 2024 | Leerink Partners | Buy | Buy | Hold |
Mirum Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 11, 2024. The company gave MIRM a "Buy" rating, the same as its previous rate.
Mirum Pharmaceuticals Financial Forecast
Mirum Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $69.55M | $47.73M | $37.50M | $31.60M | $27.91M | $18.78M | $17.48M | $12.89M | $3.14M | $5.00M | $11.00M | - | - |
| Avg Forecast | $116.45M | $108.39M | $98.55M | $88.64M | $87.57M | $81.99M | $75.03M | $70.13M | $67.87M | $38.60M | $30.44M | $28.69M | $24.65M | $20.81M | $15.42M | $8.46M | $62.67M | $1.00M | $17.40M | $12.50M | $10.00M |
| High Forecast | $116.45M | $108.39M | $98.55M | $88.64M | $87.57M | $83.25M | $75.03M | $70.13M | $70.89M | $38.60M | $30.44M | $28.69M | $24.65M | $20.81M | $15.42M | $8.46M | $62.67M | $1.00M | $17.40M | $12.50M | $10.00M |
| Low Forecast | $116.45M | $108.39M | $98.55M | $88.64M | $87.57M | $80.58M | $75.03M | $70.13M | $62.14M | $38.60M | $30.44M | $28.69M | $24.65M | $20.81M | $15.42M | $8.46M | $62.67M | $1.00M | $17.40M | $12.50M | $10.00M |
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | 1.02% | 1.24% | 1.23% | 1.10% | 1.13% | 0.90% | 1.13% | 1.52% | 0.05% | 5.00% | 0.63% | - | - |
Mirum Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 3 analysts is $70.13M, with a low forecast of $70.13M, and a high forecast of $70.13M. MIRM's average Quarter revenue forecast represents a 0.82% increase compared to the company's last Quarter revenue of $69.55M (Dec 23).
Mirum Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | $-30.07M | $-25.15M | $-70.00M | $-24.21M | $-32.61M | $-30.52M | $-29.14M | $-32.38M | $61.76M | $-41.25M | $-38.93M | $-46.96M | $-36.70M |
| Avg Forecast | $-12.29M | $-11.44M | $-10.40M | $-9.35M | $-9.24M | $-8.65M | $-7.92M | $-7.40M | $-7.16M | $-4.07M | $-3.21M | $-3.03M | $-2.60M | $-2.20M | $-1.63M | $-36.49M | $-6.61M | $-105.51K | $-1.84M | $-23.37M | $-1.06M |
| High Forecast | $-12.29M | $-11.44M | $-10.40M | $-9.35M | $-9.24M | $-8.50M | $-7.92M | $-7.40M | $-6.56M | $-4.07M | $-3.21M | $-3.03M | $-2.60M | $-2.20M | $-1.63M | $-29.19M | $-6.61M | $-105.51K | $-1.84M | $-18.70M | $-1.06M |
| Low Forecast | $-12.29M | $-11.44M | $-10.40M | $-9.35M | $-9.24M | $-8.78M | $-7.92M | $-7.40M | $-7.48M | $-4.07M | $-3.21M | $-3.03M | $-2.60M | $-2.20M | $-1.63M | $-43.78M | $-6.61M | $-105.51K | $-1.84M | $-28.05M | $-1.06M |
| Surprise % | - | - | - | - | - | - | - | - | 4.20% | 6.17% | 21.79% | 8.00% | 12.54% | 13.90% | 17.92% | 0.89% | -9.34% | 390.98% | 21.21% | 2.01% | 34.78% |
4 analysts predict MIRM's average Quarter EBITDA for Mar 22 to be $-36.49M, with a high of $-29.19M and a low of $-43.78M. This is -159.08% lower than Mirum Pharmaceuticals's previous annual EBITDA (Dec 21) of $61.76M.
Mirum Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | $-33.15M | $-23.59M | $-74.04M | $-30.13M | $-36.43M | $-35.71M | $-26.92M | $-36.61M | $57.55M | $-47.11M | $-43.89M | $-50.53M | $-37.20M |
| Avg Forecast | $708.53K | $-5.35M | $-11.81M | $-19.13M | $-18.46M | $-21.23M | $-22.31M | $-19.85M | $-11.34M | $-29.68M | $-37.57M | $-41.97M | $-47.42M | $-49.53M | $-53.85M | $-41.25M | $14.33M | $-81.92M | $-30.62M | $-24.97M | $-34.57M |
| High Forecast | $708.53K | $-5.35M | $-11.81M | $-19.13M | $-18.46M | $-14.15M | $-22.31M | $-19.85M | $-6.87M | $-29.68M | $-37.57M | $-41.97M | $-47.42M | $-49.53M | $-53.85M | $-33.00M | $14.33M | $-81.92M | $-30.62M | $-19.98M | $-34.57M |
| Low Forecast | $708.53K | $-5.35M | $-11.81M | $-19.13M | $-18.46M | $-25.00M | $-22.31M | $-19.85M | $-17.18M | $-29.68M | $-37.57M | $-41.97M | $-47.42M | $-49.53M | $-53.85M | $-49.50M | $14.33M | $-81.92M | $-30.62M | $-29.97M | $-34.57M |
| Surprise % | - | - | - | - | - | - | - | - | 2.92% | 0.79% | 1.97% | 0.72% | 0.77% | 0.72% | 0.50% | 0.89% | 4.02% | 0.58% | 1.43% | 2.02% | 1.08% |
Mirum Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-41.25M, with a range of $-49.50M to $-33.00M. MIRM's average Quarter net income forecast represents a -171.68% decrease compared to the company's last Quarter net income of $57.55M (Dec 21).
Mirum Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | $46.18M | $36.53M | $32.95M | $30.22M | $26.47M | $22.51M | $20.97M | $19.12M | $19.04M | $17.35M | $13.35M | $9.48M | $7.22M |
| Avg Forecast | $163.79M | $152.46M | $138.62M | $124.67M | $123.18M | $115.33M | $105.53M | $98.64M | $95.46M | $54.29M | $42.82M | $40.35M | $34.68M | $29.27M | $21.69M | $11.90M | $88.15M | $1.41M | $24.47M | $4.68M | $14.07M |
| High Forecast | $163.79M | $152.46M | $138.62M | $124.67M | $123.18M | $117.10M | $105.53M | $98.64M | $99.71M | $54.29M | $42.82M | $40.35M | $34.68M | $29.27M | $21.69M | $11.90M | $88.15M | $1.41M | $24.47M | $5.62M | $14.07M |
| Low Forecast | $163.79M | $152.46M | $138.62M | $124.67M | $123.18M | $113.34M | $105.53M | $98.64M | $87.41M | $54.29M | $42.82M | $40.35M | $34.68M | $29.27M | $21.69M | $11.90M | $88.15M | $1.41M | $24.47M | $3.75M | $14.07M |
| Surprise % | - | - | - | - | - | - | - | - | 0.48% | 0.67% | 0.77% | 0.75% | 0.76% | 0.77% | 0.97% | 1.61% | 0.22% | 12.34% | 0.55% | 2.02% | 0.51% |
Mirum Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $98.64M, based on 3 Wall Street analysts, with a range of $98.64M to $98.64M. The forecast indicates a 113.58% rise compared to MIRM last annual SG&A of $46.18M (Dec 23).
Mirum Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | $-0.71 | $-0.00 | $-1.94 | $-0.80 | $-0.99 | $-1.02 | $-0.84 | $-1.17 | $1.88 | $-1.55 | $-1.45 | $-1.68 | $-1.43 |
| Avg Forecast | $0.01 | $-0.11 | $-0.25 | $-0.41 | $-0.39 | $-0.45 | $-0.47 | $-0.42 | $-0.24 | $-0.63 | $-0.80 | $-0.89 | $-1.00 | $-1.05 | $-1.14 | $-1.34 | $0.30 | $-1.73 | $-0.65 | $-0.71 | $-0.73 |
| High Forecast | $0.01 | $-0.11 | $-0.25 | $-0.41 | $-0.39 | $-0.30 | $-0.47 | $-0.42 | $-0.15 | $-0.63 | $-0.80 | $-0.89 | $-1.00 | $-1.05 | $-1.14 | $-1.34 | $0.30 | $-1.73 | $-0.65 | $-0.71 | $-0.73 |
| Low Forecast | $0.01 | $-0.11 | $-0.25 | $-0.41 | $-0.39 | $-0.53 | $-0.47 | $-0.42 | $-0.36 | $-0.63 | $-0.80 | $-0.89 | $-1.00 | $-1.05 | $-1.14 | $-1.34 | $0.30 | $-1.73 | $-0.65 | $-0.71 | $-0.73 |
| Surprise % | - | - | - | - | - | - | - | - | 2.96% | 0.00% | 2.44% | 0.90% | 0.99% | 0.97% | 0.74% | 0.87% | 6.20% | 0.89% | 2.24% | 2.38% | 1.95% |
According to 4 Wall Street analysts, Mirum Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-1.34, with a low estimate of $-1.34 and a high estimate of $-1.34. This represents a -171.28% decrease compared to MIRM previous annual EPS of $1.88 (Dec 21).
Mirum Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| ARQT | Arcutis Biotherapeutics | $8.72 | $31.00 | 255.50% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| IMCR | Immunocore | $31.17 | $70.75 | 126.98% | Buy |
| KALV | KalVista Pharmaceuticals | $11.63 | $26.00 | 123.56% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| MLTX | MoonLake Immunotherapeutics | $46.40 | $79.33 | 70.97% | Buy |
| MIRM | Mirum Pharmaceuticals | $40.45 | $54.50 | 34.73% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
MIRM Forecast FAQ
Is Mirum Pharmaceuticals a good buy?
Yes, according to 8 Wall Street analysts, Mirum Pharmaceuticals (MIRM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of MIRM's total ratings.
What is MIRM's price target?
Mirum Pharmaceuticals (MIRM) average price target is $54.5 with a range of $39 to $75, implying a 34.73% from its last price of $40.45. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Mirum Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for MIRM stock, the company can go up by 34.73% (from the last price of $40.45 to the average price target of $54.5), up by 85.41% based on the highest stock price target, and down by -3.58% based on the lowest stock price target.
Can Mirum Pharmaceuticals stock reach $60?
MIRM's highest twelve months analyst stock price target of $75 supports the claim that Mirum Pharmaceuticals can reach $60 in the near future.
What are Mirum Pharmaceuticals's analysts' financial forecasts?
Mirum Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $314.72M (high $315.98M, low $313.31M), average EBITDA is $-33.208M (high $-33.058M, low $-33.34M), average net income is $-81.846M (high $-74.77M, low $-85.62M), average SG&A $442.68M (high $444.45M, low $440.69M), and average EPS is $-1.733 (high $-1.583, low $-1.813). MIRM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $412.03M (high $412.03M, low $412.03M), average EBITDA is $-43.475M (high $-43.475M, low $-43.475M), average net income is $-35.584M (high $-35.584M, low $-35.584M), average SG&A $579.55M (high $579.55M, low $579.55M), and average EPS is $-0.753 (high $-0.753, low $-0.753).
Did the MIRM's actual financial results beat the analysts' financial forecasts?
Based on Mirum Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $186.37M, beating the average analysts forecast of $165.6M by 12.55%. Apple's EBITDA was $-107M, beating the average prediction of $-17.473M by 510.34%. The company's net income was $-161M, beating the average estimation of $-121M by 33.46%. Apple's SG&A was $145.88M, missing the average forecast of $232.92M by -37.37%. Lastly, the company's EPS was $-3.94, beating the average prediction of $-2.552 by 54.37%. In terms of the last quarterly report (Dec 2023), Mirum Pharmaceuticals's revenue was $69.55M, beating the average analysts' forecast of $67.87M by 2.49%. The company's EBITDA was $-30.075M, beating the average prediction of $-7.161M by 319.99%. Mirum Pharmaceuticals's net income was $-33.149M, beating the average estimation of $-11.341M by 192.29%. The company's SG&A was $46.18M, missing the average forecast of $95.46M by -51.62%. Lastly, the company's EPS was $-0.71, beating the average prediction of $-0.24 by 195.71%